Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
Date:11/18/2011

CAMBRIDGE, Mass., Nov. 18, 2011 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with erlotinib (Tarceva®), a small molecule directed at the epidermal growth factor receptor (EGFR), in three groups of patients with metastatic non-small cell lung cancer (NSCLC). 

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO )

The Phase 2 study is designed to estimate Progression Free Survival (PFS) when combining MM-121 and erlotinib in three distinct metastatic NSCLC patient populations:

  • Group A includes patients whose tumors do not have an EGFR activating mutation.  The patient's cancer must have recurred or progressed following at least one chemotherapy-containing regimen and who have not received prior EGFR targeted therapy. They will be randomized to receive either MM-121 in combination with erlotinib or erlotinib alone.
  • Group B includes patients whose tumors have an EGFR activating mutation.  The patients must have not received prior EGFR targeted therapy.  They will be randomized to receive either MM-121 in combination with erlotinib or erlotinib alone.
  • Group C includes patients whose tumors had responded to EGFR targeted therapy and have subsequently acquired resistance. They will receive MM-121 in combination with erlotinib.

The study is being conducted at multiple sites in North America, Europe and Asia. The trial is designed to enroll approximately 229 patients across all three arms.  The first patient was enrolled at the Loma Linda University Cancer Center.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack 

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process.  Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact:  Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
3. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
4. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
5. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
6. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
7. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
10. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
11. Idenix Pharmaceuticals Prices Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... , Sept. 7, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... Conference at the Grand Hyatt hotel in New York.  ... at 11:40 a.m. Eastern Time. A live ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... WILMINGTON, Del. , Sept. 6, 2017 NeuroRx, ... for Acute Suicidal Ideation and Behavior (ASIB), has been granted ... for its sequential therapy of NRX-100 (ketamine HCl) followed by ... patients in a pivotal trial of this sequential therapy targeting ... bipolar depression. 1 ...
(Date:9/5/2017)...  Just 18 months after its February 2016 launch, ... the appointment of three new senior people to its ... Jones-Phillips and James Wright bring decades ... Tammy Wynne joins as Director, ... She has over ten years, experience in global market ...
Breaking Medicine Technology:
(Date:9/22/2017)... , ... September 22, 2017 , ... ... Rob Lowe, explores the world of Alzheimer’s. Alzheimer’s is a disease estimated to ... This according to information published by the Alzheimer’s Association, a leading voice in ...
(Date:9/22/2017)... Encino, CA (PRWEB) , ... September 22, 2017 ... ... ways to preserve fertility and create life. Although frozen embryos have a slight ... circumstances. , “Egg freezing is a wonderful opportunity for women undergoing medical ...
(Date:9/21/2017)... ... ... SABRE is raising awareness about personal safety with a Chicago Transit Authority ad ... Chicago, Illinois, based self-defense brand has been waiting for an opportunity like this to ... personal safety into their own hands. , The ads focus on their diverse line ...
(Date:9/21/2017)... ... September 21, 2017 , ... Bill Howe Plumbing’s mission is ... and give back to the community. For over 37 years, they have operated with ... serving plumbing in San Diego. They were chosen as the Best San ...
(Date:9/21/2017)... New York (PRWEB) , ... September 21, 2017 , ... ... named “One Yoga Mat Revolution” on 6th, 7th and 8th October at Miranda Kuo ... renowned yoga mat art pieces, such as Zen Kodo mat. Wanderlust , one ...
Breaking Medicine News(10 mins):